Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection.

Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC Jr, Lu KH, Koopmeiners JS.

Cancer Prev Res (Phila). 2019 Mar;12(3):171-184. doi: 10.1158/1940-6207.CAPR-18-0221. Epub 2019 Feb 1.

PMID:
30709840
2.

A multiplex platform for the identification of ovarian cancer biomarkers.

Boylan KLM, Geschwind K, Koopmeiners JS, Geller MA, Starr TK, Skubitz APN.

Clin Proteomics. 2017 Oct 10;14:34. doi: 10.1186/s12014-017-9169-6. eCollection 2017.

3.

Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers.

Kim YW, Bae SM, Lim H, Kim YJ, Ahn WS.

PLoS One. 2012;7(9):e44960. doi: 10.1371/journal.pone.0044960. Epub 2012 Sep 10.

4.

Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer.

Kim YW, Bae SM, Kim IW, Liu HB, Bang HJ, Chaturvedi PK, Battogtokh G, Lim H, Ahn WS.

Oncol Rep. 2012 Aug;28(2):585-91. doi: 10.3892/or.2012.1829. Epub 2012 May 22.

PMID:
22641176
5.

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.

Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A, Moro R.

Tumour Biol. 2011 Aug;32(4):831-8. doi: 10.1007/s13277-011-0186-1. Epub 2011 May 28.

6.

Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.

Ren X, Zhang H, Cong H, Wang X, Ni H, Shen X, Ju S.

Pathol Oncol Res. 2018 Oct;24(4):739-744. doi: 10.1007/s12253-018-0392-x. Epub 2018 Mar 8.

PMID:
29520570
7.

Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.

Blyuss O, Gentry-Maharaj A, Fourkala EO, Ryan A, Zaikin A, Menon U, Jacobs I, Timms JF.

Biomed Res Int. 2015;2015:681416. doi: 10.1155/2015/681416. Epub 2015 Dec 24.

8.

Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.

Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A, Cramer R.

Int J Gynecol Cancer. 2010 Dec;20(9):1518-24.

PMID:
21370595
9.

Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.

Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC Jr, Davis G, Serra S, Diamandis EP, Kulasingam V.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40. doi: 10.1158/1055-9965.EPI-15-1299. Epub 2016 Jul 22.

10.

CA125 and HE4: Measurement Tools for Ovarian Cancer.

Zhao T, Hu W.

Gynecol Obstet Invest. 2016;81(5):430-5. doi: 10.1159/000442288. Epub 2016 Apr 29.

PMID:
27160726
11.

Comparison of candidate serologic markers for type I and type II ovarian cancer.

Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjær SK, Shih IeM, Roden RB.

Gynecol Oncol. 2011 Sep;122(3):560-6. doi: 10.1016/j.ygyno.2011.05.039. Epub 2011 Jun 24.

12.

Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women.

Autelitano DJ, Raineri L, Knight K, Bannister K, Rice GE.

J Transl Med. 2012 Mar 12;10:45. doi: 10.1186/1479-5876-10-45.

13.

Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V.

Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.

14.

Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.

Gąsiorowska E, Michalak M, Warchoł W, Lemańska A, Jasiński P, Spaczyński M, Nowak-Markwitz E.

Ginekol Pol. 2015 Feb;86(2):88-93.

PMID:
25807831
15.

New tumor markers: CA125 and beyond.

Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review.

16.

Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer.

Park Y, Kim Y, Lee EY, Lee JH, Kim HS.

Int J Cancer. 2012 Mar 1;130(5):1136-44. doi: 10.1002/ijc.26129. Epub 2011 Jun 14.

17.

Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.

Kristjansdottir B, Levan K, Partheen K, Sundfeldt K.

Gynecol Oncol. 2013 Oct;131(1):52-8. doi: 10.1016/j.ygyno.2013.07.094. Epub 2013 Jul 25.

18.

Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.

Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, Ha M, Choi KH.

Clin Chem Lab Med. 2011 Mar;49(3):527-34. doi: 10.1515/CCLM.2011.085. Epub 2011 Feb 15.

PMID:
21320028
19.

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ, Berchuck A.

Gynecol Oncol. 2008 Sep;110(3):374-82. doi: 10.1016/j.ygyno.2008.04.041. Epub 2008 Jun 27.

PMID:
18584856
20.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2018 Jun;149(3):585-591. doi: 10.1016/j.ygyno.2018.03.050. Epub 2018 Mar 21.

PMID:
29572027

Supplemental Content

Support Center